Log in

NASDAQ:NVLNNovelion Therapeutics Stock Price, Forecast & News

$0.68
0.00 (0.00 %)
(As of 06/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.68
Now: $0.68
$0.68
50-Day Range
$0.68
MA: $0.69
$0.70
52-Week Range
$0.54
Now: $0.68
$2.35
VolumeN/A
Average Volume200,344 shs
Market Capitalization$13.34 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.
Read More
Novelion Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVLN
CUSIPN/A
Phone617-500-7867

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$130.43 million
Book Value($4.69) per share

Profitability

Net Income$-108,330,000.00

Miscellaneous

Employees109
Market Cap$13.34 million
Next Earnings DateN/A
OptionableOptionable

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.

Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions

How has Novelion Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Novelion Therapeutics' stock was trading at $0.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVLN stock has increased by 0.0% and is now trading at $0.68. View which stocks have been most impacted by Coronavirus.

How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc (NASDAQ:NVLN) issued its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($1.03) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.90) by $0.13. The biotechnology company earned $40.71 million during the quarter, compared to analysts' expectations of $40.90 million. View Novelion Therapeutics' earnings history.

Has Novelion Therapeutics been receiving favorable news coverage?

News stories about NVLN stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novelion Therapeutics earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutNovelion Therapeutics.

Who are some of Novelion Therapeutics' key competitors?

What other stocks do shareholders of Novelion Therapeutics own?

Who are Novelion Therapeutics' key executives?

Novelion Therapeutics' management team includes the following people:
  • Mr. Benjamin S. Harshbarger, Interim CEO, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Michael D. Price, Exec. VP & CFO (Age 61)
  • Mr. Roger W. Louis, Global Chief Compliance Officer and Head of R&D (Age 63)
  • Ms. Barbara Y. Chan, VP & Chief Accounting Officer (Age 55)
  • Ms. Amanda Murphy, Director of Investor Relations & Corp. Communications

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN."

How do I buy shares of Novelion Therapeutics?

Shares of NVLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of NVLN stock can currently be purchased for approximately $0.68.

How big of a company is Novelion Therapeutics?

Novelion Therapeutics has a market capitalization of $13.34 million and generates $130.43 million in revenue each year. Novelion Therapeutics employs 109 workers across the globe.

What is Novelion Therapeutics' official website?

The official website for Novelion Therapeutics is www.novelion.com.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company can be reached via phone at 617-500-7867 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.